References
1. https://covid19.who.int/(accessed August 29, 2020).
2. Linla K, Peirlinck M, Kuhl E. The reproduction number of COVID-19 and
its correlation with public health interventions. Comput Mech 2020;28:
1-16.
3. Shyr ZA, Gorshkov K, Z Chen CZ, Zheng W. Drug discovery strategies
for SARS-CoV-2. J Pharmacol Exp Ther 2020; Jul 28. doi:
10.1124/jpet.120.000123.
4. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug
discovery and therapeutic options. Nat Rev Drug Discov 2016;15: 327-47.
5. De Clercq E, Li G. Approved antiviral drugs over the past 50 years.
Clin Microbiol Rev 2016;29: 695-747.
6. Chien M, Anderson TK, Jockusch S, et al. Nucleotide analogues as
inhibitors of SARS-CoV-2 polymerase, a Key Drug Target for COVID-19. J
Proteome Res 2020. Aug 5 doi: 10.1021/acs.jproteome.0c00392.
Figure legends
Figure 1. The patient who developed SARS-CoV-2 IgG antibody (above) and
the test result of the patient’s wife who receives Tenofovir (below)
[Novacheck Diagnostic Kit (Colloidal Gold) for IgG/IgM antibody to
SARS CoV-2]